Alnylam Pharmaceuticals (ALNY) vs BioNTech (BNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioNTech (BNTX) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, losing 13.4% versus a loss of 50.2%. Over five years, ALNY leads with a +7.7% price change compared with -62.8% for BNTX. Alnylam Pharmaceuticals is the larger company by market cap ($30.90 billion vs $24.12 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | BNTX |
|---|---|---|
| Share price | $230.91 | $96.03 |
| Market cap | $30.90B | $24.12B |
| 1-day change | +2.84% | +4.31% |
| YTD return | -43.54% | -3.30% |
| 1-year return | -50.18% | -13.38% |
| 5-year return | +7.66% | -62.83% |
| P/E ratio (TTM) | 38.94 | — |
| Forward P/E | 18.59 | — |
| EPS (TTM) | $5.93 | $-7.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | — |
| Revenue growth (YoY) | +65.19% | — |
| Net income (latest FY) | $313.75M | — |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | — |
| 52-week high | $495.55 | $124.00 |
| 52-week low | $197.81 | $79.52 |
| Distance from 52-week high | -53.40% | -22.56% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +60.72% | +20.58% |
| Average volume | 1.78M | 1.16M |
| Shares outstanding | 133.81M | 251.20M |
| Employees | 2,500 | 7,807 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNTX has outperformed ALNY by 36.8 percentage points over the past year.
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
ALNY vs BNTX FAQ
Which is bigger, Alnylam Pharmaceuticals or BioNTech?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $30.90B compared with $24.12B for BioNTech (BNTX).
Which stock has performed better over the past year, ALNY or BNTX?
BNTX returned -13.38% over the past 12 months, compared with -50.18% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and BioNTech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alnylam Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech.